TITLE

BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)

AUTHOR(S)
Santamaría, Carlos; Chillón, María C.; García-Sanz, Ramón; Pérez, Cristina; Caballero, María D.; Mateos, María V.; Ramos, Fernando; de Coca, Alfonso García; Alonso, José M.; Giraldo, Pilar; Bernal, Teresa; Queizán, José A.; Rodríguez, Juan N.; Puig, Noemí; Balanzategui, Ana; Sarasquete, María E.; Alcoceba, Miguel; Díaz-Mediavilla, Joaquín; Miguel, Jesús San; González, Marcos
PUB. DATE
May 2010
SOURCE
Annals of Hematology;May2010, Vol. 89 Issue 5, p453
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
We have analyzed brain and acute leukemia, cytoplasmic ( BAALC) gene expression and other genetic markers ( ERG, EVI1, MN1, PRAME, WT1, FLT3, and NPM1 mutations) in 127 intermediate-risk acute myeloid leukemia (AML) patients: 98 cytogenetically normal and 29 with intermediate-risk cytogenetic alterations. High versus low BAALC expressers showed a higher refractoriness to induction treatment (31% vs 10%; p = .005), lower complete remission rate after salvage therapy (82% vs 97%; p = .010), and lower 3-year overall (23% vs 58%, p < .001) and relapse-free survival (26% vs 52%, p = .006). Similar results were found when cytogenetic subgroups were analyzed separately. Multivariate models confirmed the unfavorable prognosis of this marker. In conclusion, BAALC is a relevant prognostic marker in intermediate-risk AML.
ACCESSION #
48600669

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics